阿昔莫司联合非诺贝特治疗高脂血症的临床效果

Therapeutic effects of acipimox combined with fenofibrate on hyperlipidemia

目的研究阿昔莫司联合非诺贝特治疗高脂血症的效果。方法选取2020年1~8月收治的部分高脂血症患者80例为研究对象,分为对照组与观察组,每组40例。对照组给予口服非诺贝特治疗,观察组给予阿昔莫司联合非诺贝特治疗,比较2组患者治疗前后血脂各指标、SAS评分、SDS评分、SF-36评分、不良反应发生率。结果治疗前2组患者血脂各指标(LDL-L、HDL-L、TG、TC)差异无统计学意义(P>0.05),治疗后观察组患者各项指标优于对照组,差异均有统计学意义(P<0.05)。治疗前2组患者SAS、SDS评分差异无统计学意义(P>0.05),治疗后观察组情况优于对照组,差异有统计学意义(P<0.05)。治疗前2组患者SF-36评分差异无统计学意义(P>0.05),治疗后观察组情况优于对照组,差异有统计学意义(P<0.05)。观察组患者不良反应与对照组比较并未增加。结论阿昔莫司联合非诺贝特治疗高脂血症的效果优于单一使用非诺贝特治疗,患者血脂各项指标得到优化,临床疗效明显,不良反应并未增加,应在临床实践中予以推广。

Objective To investigate the therapeutic effects of acipimox combined with fenofibrate on hyperlipidemia.Methods Eighty patients with hyperlipidemia,who were treated from January to August 2020,were divided into control group(n=40)and observation group(n=40).The patients in control group were treated with fenofibrate while those in observation group were treated with acipimox combined with fenofibrate.The blood lipid indexes,SAS score,SDS score,SF36 score and incidence of adverse reactions before and after treatment were observed and compared between the two groups.Results Before treatment,there were no significant differences in blood lipid indexes(LDL-L,HDL-L,TG,TC)as well as SAS scores,SDS scores and SF36 scores between the two groups(P>0.05).After treatment,these indexes in observation group were superior to those in control group(P<0.05).There were no significant differences in theincidence rates of adverse reactions between the two groups(P>0.05).Conclusion Acipimox combined with fenofibrate is more effective in treating hyperlipidemia,which can improve the blood indexes,with obvious effect and without increasing theincidence of adverse reaction,which is worthy of clinical promotion and application.